This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Je Il Pharmaceutical Co., Ltd.. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Hanchang Lee: Innovator in Tricyclic Derivative Compounds
Introduction
Hanchang Lee is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on tricyclic derivative compounds. His research focuses on compounds that exhibit excellent activity against specific enzymes related to various diseases.
Latest Patents
Hanchang Lee holds a patent for a tricyclic derivative compound, which includes a method for preparing the compound and a pharmaceutical composition comprising it. The invention relates to novel tricyclic derivative compounds, optical isomers, racemates, or pharmaceutically acceptable salts that demonstrate inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2. These compounds have potential applications in the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, and cancer. He has 1 patent to his name.
Career Highlights
Throughout his career, Hanchang Lee has worked with various companies, including Je Il Pharmaceutical Co., Ltd. and Onconic Therapeutics Inc. His experience in these organizations has allowed him to collaborate with other professionals in the field and contribute to advancements in pharmaceutical research.
Collaborations
Hanchang Lee has collaborated with notable colleagues such as Hyunho Lee and Kwangwoo Chun. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work.
Conclusion
Hanchang Lee's innovative research on tricyclic derivative compounds positions him as a significant figure in the pharmaceutical industry. His contributions have the potential to lead to breakthroughs in the treatment of various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile